{"nctId":"NCT01436396","briefTitle":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","startDateStruct":{"date":"2011-09-07","type":"ACTUAL"},"conditions":["Dengue","Dengue Hemorrhagic Fever","Yellow Fever"],"count":792,"armGroups":[{"label":"CYD Dengue Vaccine Group","type":"EXPERIMENTAL","interventionNames":["Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus","Biological: Yellow fever vaccine","Biological: Measles, mumps, and rubella (MMR) vaccine","Biological: Pneumococcal Conjugated Vaccine","Biological: Hepatitis A Pediatric Vaccine","Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine"]},{"label":"Placebo Group","type":"EXPERIMENTAL","interventionNames":["Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus","Biological: Yellow Fever Vaccine","Biological: Placebo (NaCl)","Biological: Measles, mumps, and rubella vaccine","Biological: Pneumococcal Conjugated Vaccine","Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine","Biological: Hepatitis A Pediatric Vaccine"]}],"interventions":[{"name":"Live, attenuated dengue serotype 1, 2, 3, and 4 virus","otherNames":["CYD Dengue Vaccine"]},{"name":"Yellow fever vaccine","otherNames":["Stamaril®"]},{"name":"Measles, mumps, and rubella (MMR) vaccine","otherNames":["MMR vaccine"]},{"name":"Pneumococcal Conjugated Vaccine","otherNames":[]},{"name":"Hepatitis A Pediatric Vaccine","otherNames":[]},{"name":"Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine","otherNames":["DTaP IPV//Hib Vaccine"]},{"name":"Live, attenuated dengue serotype 1, 2, 3, and 4 virus","otherNames":["CYD dengue vaccine"]},{"name":"Yellow Fever Vaccine","otherNames":["Stamaril®"]},{"name":"Placebo (NaCl)","otherNames":["NaCl 0.9%"]},{"name":"Measles, mumps, and rubella vaccine","otherNames":["MMR vaccine"]},{"name":"Pneumococcal Conjugated Vaccine","otherNames":[]},{"name":"Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine","otherNames":["DTaP IPV//Hib Vaccine"]},{"name":"Hepatitis A Pediatric Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 12 to 13 months on the day of inclusion.\n* Born at full term of pregnancy (\\>=37 weeks) and with a birth weight \\>=2.5 kg as reported by the parent/legally acceptable representative.\n* Participant in good health, based on medical history and physical examination.\n* Participant had completed his/her vaccination schedule according to the official immunization calendar of Colombia and/or Peru, respectively.\n* Informed consent form had been signed and dated by the parent(s) or other legally acceptable representative (and by 2 independent witnesses if required by local regulations).\n* Participant and parent/legally acceptable representative/tutor able to attend all scheduled visits and to comply with all trial procedures.\n\nExclusion Criteria:\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.\n* Planned participation in another clinical trial during the present trial period.\n* Planned receipt of any vaccine in the 4 weeks following first trial vaccination.\n* Previous vaccination against YF, hepatitis A, or measles, mumps and rubella.\n* Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 weeks or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Personal known seropositivity for human immunodeficiency virus (HIV) as reported by the parent/legally acceptable representative.\n* History of previous maternal vaccination against YF as reported by the parent/legally acceptable representative.\n* Personal history of YF or dengue infection/disease as reported by the parent/legally acceptable representative.\n* Known systemic hypersensitivity to any of the vaccine components of the vaccines that were used in the trial, or history of a life-threatening reaction to the vaccines used in the trial or to vaccines containing any of the same substances.\n* History of contraindication to receipt of vaccines containing components of Stamaril® (yellow fever vaccine), measles, mumps and rubella vaccine, hepatitis A vaccine, pneumococcal conjugated vaccine or of diphtheria (D) toxoid, tetanus (T) toxoid, pertussis toxoid (PT), filamentous hemagglutinin (FHA), polyribosylribitol phosphate (PRP) and polio or other diphtheria, tetanus and pertussis vaccine (e.g., DTwP).\n* Thrombocytopenia, as reported by the parent/legally acceptable representative.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular (IM) vaccination.\n* History of central nervous system disorder or disease, including seizures.\n* Personal history of thymic pathology (e.g., thymoma), and/or thymectomy.\n* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.\n* Identified as a child (adopted or natural) of the Investigator or of employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"13 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \\>=10 (1/dilution \\[dil\\]) in flavivirus non-immune participants (defined as those with YF antibodies \\<10 \\[1/dil\\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \\>= 10 (1/dil) in participants YF-seronegative at baseline or 4-fold increase from pre- to post-YF antibody titers in participants YF-seropositive at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTs against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.64","spread":null},{"groupId":"OG001","value":"5.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369","spread":null},{"groupId":"OG001","value":"423","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTs ratios against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"39.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \\>=10 (1/dil) regardless of the flavivirus status of participants at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"99.7","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue plaque reduction neutralization test (PRNT) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.08","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.10","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","spread":null},{"groupId":"OG001","value":"5.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"43.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null},{"groupId":"OG001","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"74.6","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTRs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":null},{"groupId":"OG001","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":null},{"groupId":"OG001","value":"6.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.55","spread":null},{"groupId":"OG001","value":"3.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"4.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.82","spread":null},{"groupId":"OG001","value":"2.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.26","spread":null},{"groupId":"OG001","value":"7.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. Seroconversion was defined as antibody titers \\>= 10 (1/dil) against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.2","spread":null},{"groupId":"OG001","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against at least 1, 2, 3, or 4 serotypes (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"93.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"87.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"41.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV immune participants at baseline were defined as those participants with \\>= 10 (1/dil) for at least 1 serotype with the parental dengue virus strain or for YF virus.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.96","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null},{"groupId":"OG001","value":"59.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"133","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":null},{"groupId":"OG001","value":"6.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"95.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-non-immune participants at baseline were defined as those participants with \\<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.6","spread":null},{"groupId":"OG001","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"37.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.4","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null},{"groupId":"OG001","value":"72.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-immune participants at baseline were defined as those participants with \\>= 10 (1/dil) for at least 1 serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strain or for YF virus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null},{"groupId":"OG001","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV non-immune participants at baseline were defined as those participants with \\<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"51.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"87.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":null},{"groupId":"OG001","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"97.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo","description":"Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost and Irritability. Grade 3 Solicited injection site reactions: Tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling: \\>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \\>39.5°celsius; Vomiting: \\>= episodes per 24 hours or requiring parenteral hydration; Crying abnormal: \\>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses \\>=3 feeds/meals or refuses most feeds/meals; Irritability: inconsolable. Solicited Injection site reaction were reported separately for Stamaril®, CYD and placebo vaccine.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"19.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"20.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"16.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"40.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"27.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"44.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"33.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"33.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"34.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"17.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":394},"commonTop":["Appetite lost; Post-Any injection","Irritability; Post-Any injection","Crying abnormal; Post-Any injection","Fever; Post-Any Injection","Drowsiness; Post-Any Injection"]}}}